This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Weber JS, Yang JC, Atkins MB, Disis ML. Toxicities of Immunotherapy for the Practitioner. J Clin Oncol. 2015 Jun 20;33(18):2092-9. doi: 10.1200/JCO.2014.60.0379.Search in Google Scholar
Michielin O, van Akkooi ACJ, Ascierto PA, et al. ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo. org. Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019 Dec 1; 30(12):1884-1901. doi: 10.1093/annonc/mdz411.Search in Google Scholar
von Hebra F. Acute Exantheme und Hautkrankheiten, Verlag von Ferdinand von Enke, Erlangen, 1860.Search in Google Scholar
Paulino L, Hamblin DJ, Osondu N, Amini R. Variants of Erythema Multiforme: A Case Report and Literature Review. Cureus. 2018 Oct 16;10(10):e3459. doi: 10.7759/cureus.3459.Search in Google Scholar
Mockenhaupt M. Severe drug-induced skin reactions: clinical pattern, diagnostics and therapy. J Dtsch Dermatol Ges. 2009 Feb;7(2):142-60; quiz 161-2. English, German. doi: 10.1111/j.1610-0387.2008.06878.x.Search in Google Scholar
Damevska K, Vassileva S, Kostadinova-Kunovska S. Erythema Multiforme, Stevens–Johnson Syndrome, and Toxic Epidermal Necrolysis. In: Smoller, B., Bagherani, N. (eds) Atlas of Dermatology, Dermatopathology and Venereology. Springer, Cham. 2022. https://doi.org/10.1007/978-3-319-53808-2_60Search in Google Scholar
Martin-Liberal J, Kordbacheh T, Larkin J. Safety of pembrolizumab for the treatment of melanoma. Expert Opin Drug Saf. 2015 Jun;14(6):957-64. doi: 10.1517/14740338.2015.1021774.Search in Google Scholar
Garbe C, Eigentler TK. Vemurafenib. Recent Results Cancer Res. 2018; 211:77-89. doi: 10.1007/978-3-319-91442-8_6.Search in Google Scholar
Wantz M, Spanoudi-Kitrimi I, Lasek A. Nécrolyse épidermique toxique au vemurafenib [Vemurafenib-induced toxic epidermal necrolysis]. Ann Dermatol Venereol. 2014 Mar;141(3):215-8. French. doi: 10.1016/j.annder.2013.10.054.Search in Google Scholar
McFarlane T, Rehman N, Wang K, et al. Cutaneous toxicities of new targeted cancer therapies: must know for diagnosis, management, and patient-proxy empowerment. Ann Palliat Med. 2020 May;9(3):1296-1306. doi: 10.21037/apm.2019.08.05.Search in Google Scholar
Haanen JBAG, Carbonnel F, Robert C, et al. ESMO Guidelines Committee. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017 Jul 1;28(suppl_4):iv119-iv142. doi: 10.1093/annonc/mdx225. Erratum in: Ann Oncol. 2018 Oct 1;29(Suppl 4):iv264-iv266.Search in Google Scholar
Hashimoto H, Ito T, Ichiki T, et al. The Clinical and Histopathological Features of Cutaneous Immune-Related Adverse Events and Their Outcomes. J Clin Med. 2021 Feb 12;10(4):728. doi: 10.3390/jcm10040728.Search in Google Scholar
Sibaud V, Meyer N, Lamant L, et al. Dermatologic complications of anti-PD-1/PD-L1 immune checkpoint antibodies. Curr Opin Oncol. 2016 Jul;28(4):254-63. doi: 0.1097/CCO.0000000000000290.Search in Google Scholar
Sibaud V. Dermatologic Reactions to Immune Checkpoint Inhibitors: Skin Toxicities and Immunotherapy. Am J Clin Dermatol. 2018 Jun;19(3):345-361. doi: 10.1007/s40257-017-0336-3.Search in Google Scholar
Coleman EL, Olamiju B, Leventhal JS. The life-threatening eruptions of immune checkpoint inhibitor therapy. Clin Dermatol. 2020 Jan-Feb;38(1):94-104. doi: 0.1016/j.clindermatol.2019.10.015.Search in Google Scholar
Geisler AN, Phillips GS, Barrios DM, et al. Immune check-point inhibitor-related dermatologic adverse events. J Am Acad Dermatol. 2020 Nov;83(5):1255-1268. doi: 10.1016/j. jaad.2020.03.132.Search in Google Scholar
Nomura H, Takahashi H, Suzuki S, et al. Unexpected recalcitrant course of drug-induced erythema multiforme-like eruption and interstitial pneumonia sequentially occurring after nivolumab therapy. J Dermatol. 2017 Jul;44(7):818-821. doi: 10.1111/1346-8138.13810.Search in Google Scholar
Profil Orcid